Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05673876 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess the Safety and Pharmacokinetics of GDC-8264 in Combination With Standard of Care in Participants With Acute Graft-Versus-Host Disease (aGVHD)
A Phase 1 study, sponsored by Genentech.
- Completed
- Registry status
- Phase 1
- Development phase
- 7
- Enrollment target
NCT05673876 is a Phase 1 study that has completed, run by Genentech. The registered enrollment target is 7 participants.
The verdict
NCT05673876, a Phase 1 study, has completed, sponsored by Genentech.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 7 participants
- Enrollment target
Study Summary
The primary purpose of the study is to assess the safety and pharmacokinetics (PK) of GDC-8264 in participants with acute graft-versus-host disease (aGVHD).
Interventions
- DRUG GDC-8264
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2023-04-06 |
| Est. Completion | 2024-01-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05673876
The ClinicalTrials.gov registry entry for NCT05673876 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genentech, which has 332 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which GDC-8264 is the first listed.
NCT05673876 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05673876 about?
NCT05673876 is a clinical study titled "A Study to Assess the Safety and Pharmacokinetics of GDC-8264 in Combination With Standard of Care in Participants With Acute Graft-Versus-Host Disease (aGVHD)". The primary purpose of the study is to assess the safety and pharmacokinetics (PK) of GDC-8264 in participants with acute graft-versus-host disease (aGVHD).
What is the current status of trial NCT05673876?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2023-04-06. Estimated completion is 2024-01-15.
What interventions are being tested in trial NCT05673876?
The interventions under investigation include: GDC-8264 (DRUG).
Who is sponsoring clinical trial NCT05673876?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.